Table 1.
Patient and donor characteristics
| Characteristics | Haplo-SCT group | MSDT group | P value |
|---|---|---|---|
| Number of patients | 169 | 39 | |
| Median age (range), years | 24 (3–58) | 35 (9–60) | 0.001 |
| Male sex, n (%) | 107 (63.3%) | 21 (53.8%) | 0.273 |
| Diagnosis, n | |||
| B-ALL | 0.142 | ||
| Ph positive | 49 (29.0%) | 10 (25.6%) | |
| Ph negative | 120 (55.0%) | 29 (69.2%) | |
| T-ALL | 27 (16.0%) | 2 (5.1%) | |
| Disease status | 0.328 | ||
| CR1 | 131 (77.5%) | 33 (84.6%) | |
| ≥ CR2 | 38 (22.5%) | 6 (15.4%) | |
| Median level of pre-transplant MRD (range)# | 0.07% (0.001–6.01%) | 0.05% (0.001–3.02%) | 0.581 |
| Median time from diagnosis to transplant (months, range) | 6.5(3–72) | 6.0(3–192) | 0.803 |
| Donor-recipient sex matched grafts, n (%) | 0.314 | ||
| Male-male | 76 (45.0%) | 13 (33.3%) | |
| Male-female | 44 (26.0%) | 10 (25.6%) | |
| Female-male | 31 (18.3%) | 8 (20.5%) | |
| Female-female | 18 (10.7%) | 8 (20.5%) | |
| Donor-recipient relationship, n (%) | NA | ||
| Father-child | 80 (47.3%) | 0 | |
| Mother-child | 12 (7.1%) | 0 | |
| Sibling-sibling | 48 (28.4%) | 39 (100%) | |
| Child-parent | 24 (14.2%) | 0 | |
| Other | 5 (3.0%) | 0 | |
| ABO matched grafts, n (%) | 0.414 | ||
| Matched | 98 (58.0%) | 19 (48.7%) | |
| Major mismatch | 30 (17.8%) | 8 (20.5%) | |
| Minor mismatch | 33 (19.5%) | 11 (28.2%) | |
| Bi-directional mismatch | 8 (4.7%) | 1 (2.6%) | |
| Cell compositions in grafts, mean (range) | |||
| Infused nuclear cells, 108/kg | 8.16 (5.53–15.67) | 8.14 (5.32–13.14) | 0.711 |
| Infused CD34+ cells, 106/kg | 2.24 (0.82–8.07) | 2.45 (0.79–6.39) | 0.111 |
| Intervention for positive MRD post-HSCT among all patients, n (%) | 39 (21%) | 16 (41%) | 0.027 |
| Intervention among positive MRD post-HSCT patients, n (%) | 39/45 (87%) | 16/17(94%) | 0.662 |
| Intervention methods among positive MRD post-HSCT patients, n (%) | 0.833 | ||
| Interferon-α | 29 (64%) | 11 (65%) | |
| Donor lymphocyte infusion | 6 (13%) | 3 (18%) | |
| Targeted drug | 4 (9%) | 2 (12%) | |
| No intervention | 6 (13%) | 1 (6%) | |
The percentages of total patients either in Haplo-SCT group or MSDT group
Haplo-SCT haploidentical stem cell transplantation, MSDT human leukocyte antigen-matched sibling donor transplantation, ALL acute lymphoblastic leukemia, Ph Philadelphia-chromosome, CR complete remission, MRD minimal (measurable) residual disease, MA myeloablative conditioning regimen, NS no significance, DLI donor lymphocyte infusions
#Indicate the percentages of MRD in total nuclear cells of bone marrow detected by multiparameter flow cytometry